Akston’s AKS-699 Demonstrates Pruritus Control Sustained Through One Year, Comparable to lokivetmab with Fewer Treatments, in Head-to-Head Canine IL-31 Challenge Study

Data presented at the North American Veterinary Dermatology Forum (NAVDF) demonstrated greater than 80% reduction in pruritus sustained through one year following an initial three-dose induction regimen and a single six-month booster, with antipruritic activity comparable to lokivetmab. In a head-to-head canine IL-31 challenge study, AKS-699 demonstrated pruritus control comparable to lokivetmab while requiring substantially […]